Based in Rockville, Maryland, OncoC4 is a privately held, late clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biologics for the potential treatment of cancer. Its lead clinical candidate is BNT316/ONC-392, a next generation anti-CTLA-4 antibody that is designed to allow CTLA-4 to recycle and maintain its protective function against autoimmune diseases while enhancing anti-tumor activity at the same time. In addition, OncoC4 has a pipeline of potentially first-in-class preclinical product candidates focusing on the CD24-Siglecs cancer immune evasion pathway.
Company Details
- Employees
- 63
- Founded
- -
- Address
- 9640 Medical Center Dr, Rockville,maryland 20850,united States
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.OncoC4.com
- Keywords
- Technician jobs.
- HQ
- Rockville, Maryland
Oncoc4, Inc. Questions
Oncoc4, Inc.'s website is http://www.OncoC4.com
Oncoc4, Inc.'s LinkedIn profile is https://www.linkedin.com/company/oncoc4
Oncoc4, Inc. has
63 employees.
View email and phone details for 63
employees at Oncoc4, Inc..
Oncoc4, Inc.'s industry is
Pharmaceutical Manufacturing
Oncoc4, Inc.'s top competitors are
Biontech Se,
Cogentis Therapeutics, Inc.,
Kaigene, Inc,
Lanova Medicines,
Astrazeneca,
Nextcure, Inc.,
Acroimmune Biotech. Co., Ltd,
Tellus Therapeutics, Inc,
Macrogenics, Inc.,
Deka Biosciences, Inc.
Oncoc4, Inc.'s categories are Pharmaceutical Manufacturing
Oncoc4, Inc.'s founding year is 2020
